Phase II study of pembrolizumab plus nab-paclitaxel in Hormone Receptor–positive, HER2- negative metastatic breast cancer: clinical and molecular insights into response
Abstract Purpose We investigate the addition of PD-1 blockade to chemotherapy in HR + MBC to assess efficacy, safety, and changes in the tumor microenvironment utilizing serial tumor biopsies. Methods Single-arm phase 2 clinical trial (NCT02752685) of 20 HR+/HER2- MBC patients received nab-paclitaxel (100mg/m2 IV d1/8,...